Key Points
- Director Luke Evnin sold a string of mid‑November blocks — about 424,801 shares for roughly $408,000 total (including 56,992 shares on Nov 24 at $0.98) and now holds 3,314,848 shares, a ~1.7% reduction in his position.
- Werewolf Therapeutics shares opened at $0.91 and were down ~6.8%; the company has a market cap of ~$44.2M (52‑week range $0.60–$2.38) and carries a consensus analyst rating of "Moderate Buy" with an average target of $7.75 despite recent downgrades and lowered price targets.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 27,297 shares of the company's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $0.92, for a total value of $25,113.24. Following the completion of the sale, the director owned 3,287,551 shares in the company, valued at approximately $3,024,546.92. This represents a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Luke Evnin also recently made the following trade(s):
- On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $55,852.16.
- On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $34,268.21.
- On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $23,505.79.
- On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $40,012.04.
- On Tuesday, November 18th, Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $31,411.68.
- On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total transaction of $34,789.95.
- On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $36,790.80.
- On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $57,204.56.
- On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $28,450.09.
- On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $40,832.52.
Werewolf Therapeutics Stock Performance
NASDAQ HOWL opened at $0.91 on Wednesday. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a 50 day moving average of $1.50 and a 200-day moving average of $1.34. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The firm has a market cap of $44.19 million, a price-to-earnings ratio of -0.56 and a beta of 0.73.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Werewolf Therapeutics
Several large investors have recently made changes to their positions in HOWL. MPM Asset Management LLC boosted its holdings in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock valued at $4,189,000 after acquiring an additional 25,688 shares during the last quarter. MPM Bioimpact LLC lifted its position in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Bank of America Corp DE boosted its stake in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock worth $2,774,000 after buying an additional 109,796 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter worth approximately $409,000. Institutional investors and hedge funds own 64.84% of the company's stock.
Wall Street Analyst Weigh In
HOWL has been the topic of several research analyst reports. JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a report on Thursday, August 21st. Citigroup reaffirmed a "market outperform" rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Zacks Research lowered shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Finally, Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a research note on Tuesday, November 18th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $7.75.
View Our Latest Report on HOWL
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
